A Study of Brexpiprazole in Patients With Major Depressive Disorder
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess
the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned
open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.